Literature DB >> 15789947

Validation of the FACT-BRM with interferon-alpha treated melanoma patients.

Amber G Paterson1, Peter C Trask, Lynne I Wagner, Peg Esper, Bruce Redman.   

Abstract

The somatic, neurocognitive, and psychiatric side effects of biological response modifiers (BRMs) have been documented in specific patient samples. Although these side effects likely have a predictable impact on patients quality of life (QOL), no instrument currently measures the cumulative effect of the various complaints patients' report. The current study investigated the reliability and validity of the Functional Assessment of Cancer Treatment-Biological Response Modifier (FACT-BRM) scale for measuring QOL in a sample of melanoma patients receiving interferon. Measures of distress, depression, and fatigue were also obtained using standardized, well-validated instruments. Results indicate increased symptom burden, depression, and fatigue, and decreased quality of life over 4 months of IFN therapy. The FACT-BRM demonstrated good psychometrics and sensitivity to change, and thus appears to be a good instrument for measuring QOL in patients receiving BRMs.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15789947     DOI： 10.1007/s11136-004-1694-x

Source DB:  PubMed          Journal:  Qual Life Res        ISSN： 0962-9343            Impact factor:   4.147


  19 in total

1.  Prophylactic treatment of depression induced by interferon-alpha.

Authors:  P Hauser; R Soler; S Reed; R Kane; M Gulati; J Khosla; M A Kling; A D Valentine; C A Meyers
Journal:  Psychosomatics       Date:  2000 Sep-Oct       Impact factor: 2.386

Review 2.  Treatment of chronic hepatitis C in individuals with pre-existing or confounding neuropsychiatric disease.

Authors:  D H Van Thiel; L Friedlander; N De Maria; P J Molloy; R J Kania; A Colantoni
Journal:  Hepatogastroenterology       Date:  1998 Mar-Apr

3.  The revised Piper Fatigue Scale: psychometric evaluation in women with breast cancer.

Authors:  B F Piper; S L Dibble; M J Dodd; M C Weiss; R E Slaughter; S M Paul
Journal:  Oncol Nurs Forum       Date:  1998-05       Impact factor: 2.172

Review 4.  Safety profile of interferon-alpha therapy.

Authors:  K Weiss
Journal:  Semin Oncol       Date:  1998-02       Impact factor: 4.929

5.  The MOS short-form general health survey. Reliability and validity in a patient population.

Authors:  A L Stewart; R D Hays; J E Ware
Journal:  Med Care       Date:  1988-07       Impact factor: 2.983

6.  Low-dose recombinant IL-2 induces psychological changes: monitoring by Minnesota Multiphasic Personality Inventory (MMPI).

Authors:  Claudia Pizzi; Michele Caraglia; Maria Cianciulli; Antonietta Fabbrocini; Anna Libroia; Elide Matano; Alma Contegiacomo; Salvatore Del Prete; Alberto Abbruzzese; Angelo Martignetti; Pierosandro Tagliaferri; Angelo Raffaele Bianco
Journal:  Anticancer Res       Date:  2002 Mar-Apr       Impact factor: 2.480

7.  Longitudinal course of depression, fatigue, and quality of life in patients with high risk melanoma receiving adjuvant interferon.

Authors:  Peter C Trask; Amber G Paterson; Peg Esper; Jason Pau; Bruce Redman
Journal:  Psychooncology       Date:  2004-08       Impact factor: 3.894

8.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.

Authors:  N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes
Journal:  J Natl Cancer Inst       Date:  1993-03-03       Impact factor: 13.506

9.  Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma.

Authors:  Omar Eton; Michael G Rosenblum; Sewa S Legha; Wehei Zhang; Mary Jo East; Agop Bedikian; Nicholas Papadopoulos; Antonio Buzaid; Robert S Benjamin
Journal:  Cancer       Date:  2002-07-01       Impact factor: 6.860

Review 10.  Clinical toxicity of interferons in cancer patients: a review.

Authors:  J R Quesada; M Talpaz; A Rios; R Kurzrock; J U Gutterman
Journal:  J Clin Oncol       Date:  1986-02       Impact factor: 44.544
View more
  4 in total

1.  Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III-IV melanoma in phase III trial E1609.

Authors:  Uma N Rao; Laurie E McLouth; Yue Zheng; Stephanie Smith; F Stephen Hodi; Gary I Cohen; Thomas T Amatruda; Shaker R Dakhil; Brendan D Curti; Ibrahim Nakhoul; Sreenivasa R Chandana; Charles L Bane; David E Marinier; Sandra J Lee; Vernon K Sondak; John M Kirkwood; Ahmad A Tarhini; Lynne I Wagner
Journal:  Qual Life Res       Date:  2022-08-27       Impact factor: 3.440

2.  Retrospective trial of complete decongestive physical therapy for lower extremity secondary lymphedema in melanoma patients.

Authors:  Eli Carmeli; Roberto Bartoletti
Journal:  Support Care Cancer       Date:  2010-01-12       Impact factor: 3.603

3.  Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment.

Authors:  Dennis A Revicki; Alfons J M van den Eertwegh; Paul Lorigan; Celeste Lebbe; Gerald Linette; Christian H Ottensmeier; Shima Safikhani; Marianne Messina; Axel Hoos; Samuel Wagner; Srividya Kotapati
Journal:  Health Qual Life Outcomes       Date:  2012-06-13       Impact factor: 3.186

4.  Quality of life and cost-effectiveness of interferon-alpha in malignant melanoma: results from randomised trial.

Authors:  S Dixon; S J Walters; L Turner; B W Hancock
Journal:  Br J Cancer       Date:  2006-02-27       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.